Adámas Nanotechnologies

Contact: Olga Shenderova
Location: Raleigh, NC
Email: oshenderova@adamasnano.com
Tel: 919.618.4515
Website: http://www.adamasnano.com

Company Profile

Industry Sector: Life Sciences - Healthcare

Company Overview:
Adámas Nanotechnologies, Inc., Raleigh, NC was founded in 2010. Adámas is dedicated to development and production of nanodiamond and related technologies serving diverse markets such as:
- Non-toxic fluorescent markers for bioimaging, authentication, solar cells, fluid labeling
- Drug carriers for targeted drug delivery
- Sunscreens
- Nanolubricants (energy saving, pollution reduction)
- Seeding slurries for growth diamond films

Target Market(s): Biopharmaceutical Suppliers, healthcare products, microelectronics, energetics

Key Value Drivers

Technology*: Fluorescent Nanodiamonds (FND) for diagnostics and drug development applications.

Competitive Advantage: Market leading position, proprietary material preparation, preeminent nanodiamond scientist, IP protection

Plan & Strategy: 1. Refine FNDs for biomedical applications, 2. Partner with leading research universities/organizations and pharmaceutical suppliers to prove viability and benefits of FND technology, 3. Support partner companies in developing clinically relevant applications of FND (e.g. diagnostics), 4. Support partner companies in developing novel imaging methods where FND is an ideal marker (e.g. CLEM) 5. Support partner companies in developing non-biomedical applications of FND (authentication) 6. Continue to build IP protection

Management

Leadership:
President and CTO: Olga Shenderova
Vice President Business Development: Gary McGuire
Vice President Marketing: Kevin Smith

Scientific Advisory Board:
GE Ventures (medical imaging division)
JSR Micro (in-vitro applications)
Life Technologies (Thermo Fisher Scientific)
Philips Healthcare (Imaging division)
Siemens Healthcare diagnostics

Product Pipeline

1. Pipeline One: High brightness 10–50 nm red Fluorescent Nano-diamonds (FND)

2. Pipeline Two: Conjugation of red FNDs with proteins including biotin, streptavidin, Vascular Endothelial Growth Factor (scVEGF), a-VEGFR2

3. Pipeline Three: Optimization of FNDs from Pipeline One and Two to meet in-vivo imaging and diagnostic applications requirements.